• Molecular NameBupivacaine
  • Synonym(+-)-Bupivacaine; Bloqueina; Bupivacaina [INN-Spanish]; bupivacaine; Bupivacaine HCL; Bupivacaine HCL KIT; Bupivacainum [INN-Latin]; cBupivacaine; DL-Bupivacaine; DUR-843; LAC-43
  • Weight288.435
  • Drugbank_IDDB00297
  • ACS_NO2180-92-9
  • Show 3D model
  • LogP (experiment)3.41
  • LogP (predicted, AB/LogP v2.0)3.09
  • pka8.1
  • LogD (pH=7, predicted)2.23
  • Solubility (experiment)2.4 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.49
  • LogSw (predicted, AB/LogsW2.0)0.85
  • Sw (mg/ml) (predicted, ACD/Labs)0.2
  • No.of HBond Donors1
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds5
  • TPSA32.34
  • StatusFDA approved
  • Administrationparenteral, topical
  • PharmacologyA local anaesthetic drug belonging to the amino amide group.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding95.0
  • Volume of distribution (VD)1 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)Plasma : whole blood ratio, about 1.4.
  • MetabollsmHepatic
  • Half life1~3 h, increased in neonates
  • ExcretionRenal, 4–10%
  • Urinary ExcretionN/A
  • Clerance8 ml/min/kg.
  • ToxicityBupivacaine is several times more toxic than lidocaine. Muscular rigidity has been reported in 2 subjects having blood concentrations of 9 and 12 mg/L following the administration of approximately 210 mg, and convulsions have been reported at plasma concentrations greater than 4 mg/L.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A